Novella Clinical Inc. (formerly PharmaLinkFHI) and OSI Pharmaceuticals,
Inc. (NASDAQ: OSIP) announced today that the Companies will expand their
existing clinical service agreement. Under the terms of the new
agreement, effective February 1, 2010, Novella will provide clinical
research and related services to OSI for a period of two years as OSI
transitions its clinical operations to its new Ardsley, New York campus.
Novella will assume use of some of OSI’s facilities in Boulder and
employ members of OSI’s Boulder staff.
“We are excited to be expanding our footprint and adding to our Novella
family”
“We are excited to be expanding our footprint and adding to our Novella
family,” stated W. Richard Staub, President and Chief Executive Officer
of Novella Clinical. “This agreement offers many advantages to Novella
and will help us realize a number of our corporate objectives. As a CRO
focused on biotech and medical device companies, many of our clients are
located on the west coast and having an office in the western part of
the country will allow us to better service their needs. Additionally,
as OSI’s pipeline is primarily focused on oncology products, the OSI
staff joining Novella will bring a depth of experience that will
strengthen what is already our largest therapeutic category.”